KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Inovio Pharmaceuticals (INO) Receivables - Other (2016 - 2023)

Inovio Pharmaceuticals (INO) has disclosed Receivables - Other for 14 consecutive years, with $4.9 million as the latest value for Q1 2023.

  • Quarterly Receivables - Other rose 40.52% to $4.9 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Mar 2023, up 40.52% year-over-year, with the annual reading at $10.0 million for FY2022, 286.02% up from the prior year.
  • Receivables - Other hit $4.9 million in Q1 2023 for Inovio Pharmaceuticals, down from $10.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $10.0 million in Q4 2022 to a low of $128000.0 in Q2 2019.
  • Historically, Receivables - Other has averaged $2.7 million across 5 years, with a median of $1.3 million in 2019.
  • Biggest five-year swings in Receivables - Other: soared 2165.62% in 2020 and later tumbled 78.72% in 2021.
  • Year by year, Receivables - Other stood at $1.3 million in 2019, then crashed by 68.09% to $425000.0 in 2020, then surged by 511.76% to $2.6 million in 2021, then surged by 286.02% to $10.0 million in 2022, then plummeted by 51.18% to $4.9 million in 2023.
  • Business Quant data shows Receivables - Other for INO at $4.9 million in Q1 2023, $10.0 million in Q4 2022, and $7.5 million in Q3 2022.